Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Drug Profile

Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Alternative Names: CYC 800 series; CYC-140; CYC800; Plk1 inhibitors - Cyclacel; Polo-like kinase 1 inhibitors - Cyclacel; Research programme: cell cycle modulators - Cyclacel

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitosis inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours
  • No development reported Cancer

Most Recent Events

  • 04 Oct 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center enter into a three-year clinical collaboration agreement for CYC 140 in Haematological Malignancies
  • 04 Oct 2018 The Institutional Review Board approves a first-in-human phase I trial of CYC 140 in advanced Leukaemia and Myelodysplastic syndrome in USA
  • 04 Oct 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center plan a first-in-human phase I trial of CYC 140 in advanced Leukaemia and Myelodysplastic syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top